Racing UCB and Roivant, Argenx clears phase 2 in primary immune thrombocytopenia

Posted on: Sep 17, 2018   |   Posted by: Biotech Mag Top

Argenx has posted phase 2 data on efgartigimod in primary immune thrombocytopenia. The results hint at the efficacy of the antibody Fc fragment in patients with the autoimmune...

Other Posts from Biotech Mag Top